Atossa Therapeutics(ATOS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factor • Released a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)- endoxifen which met the primary endpoint with 95 percent (19/20 patients) ...